Numerous drug treatments that have recently entered the clinic or clinical trials have their
genesis in zebrafish. Zebrafish are well established for their contribution to developmental …

For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefited many patients. However, novel approaches …

Molecular glue compounds induce protein–protein interactions that, in the context of a
ubiquitin ligase, lead to protein degradation. Unlike traditional enzyme inhibitors, these …

Cell-based therapies are emerging as effective agents against cancer and other diseases.
As autonomous “living drugs,” these therapies lack precise control. Chimeric antigen …

Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …

There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with
driver gene mutations arise in the background of clonal hematopoiesis (CH) under the …

Chemical biology strategies for directly perturbing protein homeostasis including the
degradation tag (dTAG) system provide temporal advantages over genetic approaches and …

Thalidomide and its derivatives are powerful cancer therapeutics that are among the best-
understood molecular glue degraders (MGDs). These drugs selectively reprogram the E3 …

Whereas the PROTAC approach to target protein degradation greatly benefits from rational
design, the discovery of small-molecule degraders relies mostly on phenotypic screening …

Targeted protein degradation refers to the use of small molecules to induce the selective
degradation of proteins. In its most common form, this degradation is achieved through …